Tarsus Pharmaceuticals (TARS) CEO transfers 51,885 shares to living trust

Rhea-AI Filing Summary

Tarsus Pharmaceuticals President and CEO Bobak Azamian, who is also Board Chair and a director, reported a transfer of 51,885 shares of common stock on December 4, 2025. The shares were moved for no consideration to the Bobak Azamian Living Trust, established April 16, 2018.

After the transaction, he holds 1,750 Tarsus shares directly and 863,991 shares indirectly through the trust, where he serves as trustee with voting and dispositive power over these shares. The report reflects a restructuring of how his holdings are owned rather than a cash sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azamian Bobak R.

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President/CEO and Board Chair

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		G		51,885	D	$0	1,750	D(1)
Common Stock								863,991	I(1)	By the Bobak Azamian Living Trust established April 16, 2018

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person transferred 51,885 shares of common stock to the Bobak Azamian Living Trust for no consideration. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider share transfer did Tarsus Pharmaceuticals (TARS) report?

The report shows that President, CEO and Board Chair Bobak Azamian transferred 51,885 shares of common stock on December 4, 2025.

Who received the 51,885 Tarsus Pharmaceuticals (TARS) shares?

The 51,885 shares of Tarsus common stock were transferred for no consideration to the Bobak Azamian Living Trust, established April 16, 2018.

Did Bobak Azamian receive payment for the transferred TARS shares?

No. The disclosure states that the reporting person transferred 51,885 shares of common stock to the Bobak Azamian Living Trust for no consideration.

How many Tarsus Pharmaceuticals shares does Bobak Azamian hold after the transaction?

Following the transaction, he holds 1,750 shares directly and 863,991 shares indirectly through the Bobak Azamian Living Trust.

Does Bobak Azamian still control the Tarsus shares held in the trust?

Yes. He is the trustee of the Bobak Azamian Living Trust and has voting and dispositive power with respect to the shares held there.

What is Bobak Azamian’s role at Tarsus Pharmaceuticals (TARS)?

He is a director, President/CEO, and Board Chair of Tarsus Pharmaceuticals, Inc.